Axogen, Inc. (AXGN) Stock Price & Analysis
Axogen, Inc. (AXGN) fell 3.61% to USD 46.54 as of September 8, 2026 at 16:18 UTC, according to Nexqual real-time market data.
AXGN last closed at USD 46.54; the session ranged USD 46.27–47.98 on volume of 179,719 shares. Market capitalization is —, with a 52-week range of USD 15.27–52.91 (NCM). Source: Nexqual, September 8, 2026 at 16:18 UTC.
Key Statistics (as of September 8, 2026 at 16:18 UTC)
| Price | USD 46.54 |
|---|---|
| Change | ▼ 3.61% (down) |
| Previous Close | USD 46.54 |
| Open | USD 46.54 |
| Day Range | USD 46.27 – 47.98 |
| 52-Week Range | USD 15.27 – 52.91 |
| Volume | 179,719 shares |
| Market Cap | — |
| Exchange | NCM |
Technical Analysis (AXGN)
Nexqual's technical model rates AXGN "BUY" based on 4 bullish and 2 bearish signals across 127 daily candles, as of September 8, 2026 at 16:18 UTC.
| Overall Signal | BUY |
|---|---|
| RSI (14) | 48.73 (neutral) |
| vs SMA50 | Above (USD 45.22) |
| MACD | 0.84 (positive) |
From Axogen, Inc.'s Latest SEC 10-K Filing (filed 2026-02-24)
Key Strengths & Strategy (as disclosed to the SEC)
- Biologics License Application Approval On December 3, 2025, the FDA approved the BLA for Avance as an acellular nerve scaffold for the treatment of adult and pediatric patients aged one month or older with sensory nerve discontinuity (≤25mm).
- The Service Provider is a FDA registered tissue establishment and an AATB accredited organization.
- The Axogen Quality System meets the requirements set forth under 21 CFR Part 1271 for HCT/Ps, including Good Tissue Practices ("GTP") and is compliant with the 21 CFR Part 820 Quality System Regulation ("QSR").
- General We are the leading company focused specifically on the science, development, and commercialization of technologies for peripheral nerve regeneration and repair.
Partnerships
- We obtained certain economic development grants from state and local authorities totaling up to $2.7 million including $1.3 million of cash grants to offset costs to acquire and develop the APC Facility.
- In partnership with leading surgeons and healthcare providers, our team works to reverse legacy non-coverage policies for Avance Products and Axoguard products.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| ATRC | AtriCure, Inc. | USD 52.96 | ▲ 0.95% |
| BLFS | BioLife Solutions, Inc. | USD 36.02 | ▲ 1.38% |
| ANAB | AnaptysBio, Inc. | USD 57.68 | ▲ 0.38% |
| LIVN | LivaNova PLC | USD 80.87 | ▼ 0.41% |
| TCMD | Tactile Systems Technology, Inc | USD 21.63 | ▼ 1.73% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: September 8, 2026 at 16:18 UTC. This page is informational and not investment advice.